PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack

New research finds that adding vorapaxar to standard antiplatelet therapy reduces the likelihood of another cardiac event in patients with a history of prior heart attack

2012-08-27
(Press-News.org) According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet.

For more than a million Americans who survive a heart attack each year, doctors routinely prescribe a daily aspirin to help prevent the formation of blood clots in the arteries which can frequently lead to another heart attack. Other platelet blockers, like clopidogrel, which also serve this purpose, are often added for up to a year, but the scientific evidence is unclear about whether adding platelet blockers to aspirin beyond this timeframe is clinically useful. Despite such therapies, these patients have an almost 15 percent chance of having another atherosclerosis-related event that brings them to the hospital within a year.

"There continues to be substantial uncertainty regarding the benefit of long-term antiplatelet therapy in addition to aspirin in patients with prior heart attacks," said Benjamin M. Scirica, M.D., M.P.H., investigator at the TIMI Study Group, a cardiologist at BWH, and one of the study's investigators. "This is the first study to show convincingly that continued, long-term, therapy beyond one year with more potent antiplatelet therapy reduces the risk of having another cardiovascular event." Previous studies in secondary prevention did not show this benefit.

Researchers from the TIMI Study Group at BWH have shown, for the first time, that adding vorapaxar, a new antiplatelet medication, on top of standard therapy which includes aspirin, is effective for long-term secondary prevention in stable patients with a prior heart attack. When used with aspirin and other standard antiplatelet therapy in a broad group of patients with previous heart attack, vorapaxar reduced the risk of cardiovascular death, heart attack or stroke by an additional 20 percent.

This randomized, double blind, placebo-controlled, multinational study followed 26,449 patients for more than two years while receiving standard antiplatelet therapy for established atherosclerosis, including previous heart attack, stroke or atherosclerotic narrowing in the arteries of the legs. Participants were randomly assigned to receive the investigational platelet blocker (2.5 mg orally once daily) with standard therapy, or a placebo with standard therapy. The overall trial results, which were presented and published in March 2012, demonstrated a 13 percent reduction in the risk of cardiovascular death, heart attack or stroke. These new findings focus specifically on the 17,779 patients with a prior heart attack.

Vorapaxar is the first of a new class of investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonists. Unlike other antithrombotic drugs, vorapaxar blocks thrombin from stimulating platelets to stick together and create clots. In addition to the benefit of reducing future cardiac events, researchers also report that this new therapy was found to increase the risk of moderate or severe bleeding in patients with prior heart attacks. Intracranial hemorrhage tended to be higher but did not differ significantly between vorapaxar than placebo (0.6 vs. 0.4 percent at 3 years),

Researchers caution that if vorapaxar becomes available for clinical use, clinicians will have to balance the antithrombotic efficacy versus the risk of bleeding for the individual patient.

"Of the groups we studied, the greatest net clinical benefit was observed in those patients who are less than 75 years old, have no history of stroke or transient ischemic attacks, and weigh at least 60 kilograms," said Scirica. "In this group of 14,909 patients, 84 percent of the group with prior heart attacks, vorapaxar reduced the risk of cardiovascular death, heart attack, or stroke by 25 percent and cardiovascular death alone by 27 percent."

### The study was funded by Merck Research Laboratories. Dr. Scirica has received research grant support and consulting fees from Merck, as well as other manufacturers of antiplatelet and anticoagulant therapies.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs more than 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.


ELSE PRESS RELEASES FROM THIS DATE:

The PURE study

2012-08-27
Munich, Germany – Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries. Results from the Prospective Urban Rural Epidemiology (PURE) study were reported here today by Professor Salim Yusuf of the Population Health Research Institute, McMaster University and Hamilton Health Sciences, in Hamilton, Canada and principal investigator of the study. The study, involving 154,000 individuals from 628 communities, ...

The DeFACTO study

2012-08-27
Munich, Germany – Data presented today from the prospective Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study show that, when compared to standard coronary angiography (CT), the non-invasive assessment of fractional flow reserve by computed tomography (FFRct) provides a more accurate determination of which lesions require invasive evaluation.(1) The results of the study were presented by Dr James K. Min, director of Cardiac Imaging Research and co-director of Cardiac Imaging at the Department of Medicine, Imaging and ...

Median follow-up results from the ALTITUDE study, stopped prematurely in December 2011

2012-08-27
Munich, Germany – Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) blockade in type 2 diabetics at high risk of cardiovascular and renal events, according to Professor Hans-Henrik Parving from Rigshospitalet, University of Copenhagen, Denmark. Presenting results from the study today, he said the treatment "may even be harmful". The ALTITUDE trial was stopped prematurely in December 2011 on recommendation ...

The TRILOGY ACS study

2012-08-27
Munich, Germany – The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke. The findings, from the phase III Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) study, were presented today at a Hot Line session of ESC Congress 2012 in Munich. TRILOGY ACS was double-blind, randomised trial ...

The PARAMOUNT study

2012-08-27
Munich, Germany – The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial. Approximately half of all heart failure patients have normal or nearly normal ejection fraction, a measure of their strength of cardiac contraction. However, while many studies have shown a benefit of pharmacological therapies in heart failure ...

The Aldo-DHF study

2012-08-27
Munich, Germany – Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012. Behind his conclusion lay results showing that mineralocorticoid receptor blockade with spironolactone improves cardiac function and structure, reduces neuroendocrine activation, and effectively reduces blood pressure in a patient population with symptomatic predominantly ...

Obesity triggers AF in fertile women

2012-08-27
Munich, Germany – Obesity triggers atrial fibrillation in fertile women, according to research presented today at the ESC Congress 2012 by Dr Deniz Karasoy from Denmark. Atrial fibrillation and obesity are among the largest public health related challenges in the western world today. Atrial fibrillation is the commonest heart rhythm disorder and is associated with increased mortality and morbidity. Previous studies have demonstrated that obesity increases the risk of new-onset atrial fibrillation in individuals with known risk factors for developing atrial fibrillation ...

Female gender increases stroke risk in AF patients aged over 75 years by 20%

2012-08-27
Munich, Germany – Female gender increases the risk of stroke in patients with atrial fibrillation (AF) aged >75 years by 20%, according to a study presented today at the ESC Congress 2012. The findings were presented by Anders Mikkelsen, from Denmark. The results suggest that female gender should not be included as an independent stroke/thromboembolism (TE) risk factor in guidelines or risk stratification schemes used in treatment of patients with atrial fibrillation. The increased risk of stroke and TE in patients with atrial fibrillation depends on additional risk ...

Women with acute heart failure have similar in-hospital mortality to men but are less treated

2012-08-27
Munich, Germany – Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece. Acute heart failure (AHF) is a frequent clinical situation with high short- and long-term mortality as well as high hospitalization rates. The Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF) is an in-hospital chart audit survey which includes patients hospitalized ...

Drug eluting stents used less often in women than men

2012-08-27
Munich, Germany – Drug eluting stents (DES) are used less often in women treated with percutaneous coronary intervention (PCI) for coronary artery disease than men treated with PCI for the same condition, according to research presented today, August 25, at the ESC Congress 2012. The findings from a country-wide Germany registry were presented by Dr Martin Russ. Coronary artery disease is still a leading cause of mortality and morbidity in Europe and worldwide. During treatment with PCI, cardiologists can use bare metal stents (BMS) or the newer DES. While they do not ...

LAST 30 PRESS RELEASES:

The Lancet: Tens of thousands of children aged under five suffering acute malnutrition in Gaza, recent estimates suggest

Prostate testing may not target those most likely to benefit, warn experts

Global analysis shows hidden damage from men’s alcohol use

DRI recognizes Ashley Cornish as the 2025 Peter B. Wagner Memorial Award Winner for Women in Atmospheric Sciences

Unlocking the blueprint for a powerful plant-based drug

Bringing modern science to vitamin biology: Isha Jain wins NIH Transformative Research Award

University of Houston scientists learn that rare bacterium ‘plays dead’ to survive

Introduced animals change how island plants spread, new global study finds

Mayo Clinic researchers discover ‘traffic controller’ protein that protects DNA, and may help kill cancer cells

Protein sidekick exhibits dual roles in stress granule assembly and disassembly

New hope for MS

Kennesaw State professor receives grant to study cancer origins

Pain and antidepressant drug combo linked to increased seizure risk in older adults

Cancer researchers shape new strategies for immunotherapy

Physical exercise can ‘train’ the immune system

Calm red brocket deer can learn to "Come" and other commands - but the flightiest, most restless individuals struggle

China, the world's largest tea producer, is predicted to experience increases in land suitable for tea-growing under climate change, with the overall range shifting northwards, per AI modeling study

Composing crews for Mars missions

Early humans butchered elephants using small tools and made big tools from their bones

1,000-year-old gut microbiome revealed for young man who lived in pre-Hispanic Mexico

Bears and pandas in captivity develop significantly different gut microbiomes compared to their wild counterparts, and giant pandas in particular have less diverse microbiomes than their wild counterp

Prenatal and postnatal support apps might not work

Dancing dust devils trace raging winds on Mars

Raging winds on Mars

Real-time biopsies uncover hidden response to glioblastoma therapy

Repeated brain tumor sampling uncovers treatment response in patients with glioblastoma

Novel immunotherapy combination destroys colorectal liver metastases

Farmed totoaba could curb poaching

Avalanches: user-carried safety device increases survival time fivefold

It’s all in your head: Select neurons in the brainstem may hold the key to treating chronic pain

[Press-News.org] Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack
New research finds that adding vorapaxar to standard antiplatelet therapy reduces the likelihood of another cardiac event in patients with a history of prior heart attack